Abstracts tagged "macrophages"

Abstract Number: 0966 • ACR Convergence 2024
CDDO-Me Attenuates Pro-fibrotic Activation in Macrophages and Fibroblasts in Systemic Sclerosis
Heetaek Yang¹, Chanhyuk Park², Chen-Yu Wang³, Emily Morris⁴, Karen Liby⁵, Michael Whitfield⁶ and Patricia Pioli², ¹Dartmouth College, West Lebanon, NH, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Dartmouth College, Lebanon, NH, ⁴Dartmouth College, Enfield, NH, ⁵Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN, ⁶Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: Systemic Sclerosis (SSc) is characterized by dysfunctional immune activation, oxidative stress, and fibrosis. In prior work, we have shown that SSc macrophages (MØs) have…
Abstract Number: 2547 • ACR Convergence 2024
Neurophysiological Phenotypes Are Uncoupled from Toll-like Receptor-Mediated Peripheral Disease in a Mouse Model of Neuropsychiatric Symptoms of Systemic Lupus Erythematosus
Cecilia Stumpf¹, Vanessa Rodriguez¹ and Carla Cuda², ¹Northwestern University, Chicago, ²Northwestern University, Chicago, IL
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with diverse clinical presentations, including neuropsychiatric symptoms (NPSLE). Despite being a major cause of morbidity…
Abstract Number: 0061 • ACR Convergence 2024
Comparative Transcriptional Profiling of IPF and RA-ILD Lung Tissue Demonstrates Both Overlapping and Distinct Cell-specific Signaling Pathways
Joshua Sciurba¹, Daniel Kass¹, Eleanor Valenzi², John Sembrat², Robert Lafyatis³ and Dana Ascherman⁴, ¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: Transcriptional profiling represents a powerful tool for deciphering disease-relevant pathways and deriving functional biomarkers. Given the shared demographic, genetic, and clinico-epidemiologic features between rheumatoid…
Abstract Number: 0972 • ACR Convergence 2024
Downregulated Fli1 in Scleroderma Myeloid Cells Contributes to Cardiac Fibrosis via a Galectin-3/mTOR Dependent Pathway
Fatima El adili¹, Moyo Mudhibadhi², Giovanni ligresti³, Maria Trojanowska² and Andreea Bujor³, ¹Boston Medical Center, Boston, MA, ²Boston university medical school, Boston, MA, ³Boston University, Boston, MA
Background/Purpose: Cardiac fibrosis is a common complication in Systemic sclerosis (SSc), but the pathogenesis is largely unknown. We have previously shown that monocytes isolated from…
Abstract Number: 2550 • ACR Convergence 2024
Infiltrating and Resident Macrophages in Lupus Nephritis: Scar Associated Macrophage Phagocytic Dysfunction and Fibroblast Activation
Chirag Raparia¹, Paul Hoover², Arnon Arazi³, Nir Hacohen⁴ and Anne Davidson⁵, ¹Donald and Barbara Zucker School of Medicine At Hofstra/Northwell, Shoreham, NY, ²Brigham and Women's Hospital, SWAMPSCOTT, MA, ³Feinstein Institutes for Medical Research, Melrose, MA, ⁴Broad Institute of MIT and Harvard, Boston, MA, ⁵Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: Lupus nephritis (LN) is driven by a heterogeneous population of renal macrophages. We have previously reported that the renal macrophage subpopulations are similar in…
Abstract Number: 0062 • ACR Convergence 2024
Pro-Fibrotic Effects of Malondialdehyde-Acetaldehyde-Adducted and/or Citrullinated Proteins on Macrophages and Human Lung Fibroblasts
Lauren Klingemann¹, Nozima Aripova¹, Nigina Aripova², Michael Duryee¹, Carlos Hunter¹, Jill Poole¹, Bryant England¹, Ted Mikuls¹ and Geoffrey Thiele¹, ¹University of Nebraska Medical Center, Omaha, NE, ²WUSTL, St. Louis, MO
Background/Purpose: Clinically evident rheumatoid arthritis-associated interstitial lung disease (RA-ILD) affects approximately 10-15% of patients with rheumatoid arthritis (RA) and accounts for the most overrepresented cause…
Abstract Number: 0973 • ACR Convergence 2024
Mechano-transduction via MRTF-A Pathway Is Required for Cytokine Release by Scleroderma Macrophages
Sandra Lopez Garces¹, Guan Hui Tricia Lim², Jorlin Liu³, Maahia Choudhary³, Juno Erin Vimalenthiran,³, Angela Tam¹, David Abraham³, Christopher Denton⁴, Bahja Ahmed Abdi¹ and Richard Stratton⁵, ¹University College London, London, United Kingdom, ²Centre for Rheumatology and Connective Tissue Diseases, University College London Medical School, Royal Free Campus, London, United Kingdom, ³UCL, London, United Kingdom, ⁴University College London, Northwood, United Kingdom, ⁵UCL, London, England, United Kingdom
Background/Purpose: In keeping with hallmark clinical evidence of stiffening and fibrotic thickening of the skin, we and others have previously demonstrated a role for the…
Abstract Number: 2593 • ACR Convergence 2024
A Long-term Synovial Tissue 3D Model Incorporating Fibroblasts, Macrophages, Endothelial Cells, and Other Immune Cells Such as Innate Lymphoid Cells Enables Animal Model-Independent Rheumatoid Arthritis Research
Miriam Bollmann¹, Oskar Landberg², Negar Ayoubzadeh², Charlotte A. Jonsson², Inger Gjertsson² and Mattias Svensson², ¹University of Gothenburg, Göteborg, Sweden, ²University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory joint disease with multiple tissues contributing to its pathology, including the synovial membrane. The RA synovial membrane…
Abstract Number: 0074 • ACR Convergence 2024
Tofacitinib Therapy Ameliorates Inflammation in a Mouse Model of Psoriasis and Arthritis by Inducing Type 2 Immunity
Maria de la Luz Garcia-Hernandez¹, Javier Rangel-Moreno¹, Ananta Paine², Angel Rangel-Garcia¹, Marissa Krantz³, Delaney Martino¹, Marc Nuzzo¹ and Christopher Ritchlin⁴, ¹University of Rochester, Rochester, NY, ²ORNA Tx, Southborough, MA, ³University of Rochester, Rochester, NY, ⁴Department of Medicine, Allergy, Immunology, and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY
Background/Purpose: Psoriatic arthritis (PsA), a chronic progressive inflammatory arthritis, affects peripheral joints and causes patient disability. PsA patients also have skin plaques initiated by activation…
Abstract Number: 1396 • ACR Convergence 2024
Low CD47 Expression on B Cells, Induces High B Cell Phagocytosis by Macrophages and Is a Predictive Biomarker of Anti-rituximab Antibodies and Lower Response in Rheumatoid Arthritis
Samuel Bitoun¹, Bineta Ly², Audrey Paoletti², Catherine Menier Menier³, Marc Pallardy⁴, Bernard Maillere⁵ and Xavier Mariette⁶, and ABIRISK consortium, ¹Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicetre, France, ²Rheumatology departement, Université Paris Saclay, Inserm UMR 1184,Hopital Bicêtre, APHP, FHU CARE, Le Kremlin Bicêtre, France, ³1 CEA, INRAE, Département Médicaments et Technologies pour la Santé, SIMoS, Université de Paris-Saclay, Gif sur Yvette, France, ⁴Université Paris-Saclay, INSERM, Inflammation Microbiome Immunosurveillance, Orsay, France, ⁵CEA, INRAE, Département Médicaments et Technologies pour la Santé, SIMoS, Université de Paris-Saclay, Gif sur Yvette, France, ⁶Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France
Background/Purpose: Rituximab (RTX) provides long lasting efficacy in the control of rheumatoid arthritis. Among factors associated with RTX failure are the occurrence of anti-drug antibodies…
Abstract Number: 2594 • ACR Convergence 2024
A Novel Therapeutically Active CSF-1R Agonist Promotes Tissue Macrophages Inflammation Resolution and Induces Tissue Repair Pathways
Saul Kivimae¹, Sandip Mukherjee², Phi Quach³, Rhoneil Pena⁴, Olga Zemska³, Michal Olszewski⁵, Jicai Huang³, Michael Labson⁶, Donald Walker¹, Mekhala Maiti⁷, Chakrapani Tripathi⁸, Thomas Chang³, Suresh Adapala⁹, Damon Hamel³, Katherine Brendza³, Takahiro Miyazaki³ and Jonathan Zalevsky¹, ¹Nektar Therapeutics, San Francisco, CA, ²Nurix Therapeutics, San Francisco, ³Nektar Therapeutics, San Francisco, ⁴Sutro Biopharma, South San Francisco, ⁵Vaxcyte, San Francisco, ⁶Guardant Health, Palo Alto, ⁷Alumis, Inc, South San Francisco, ⁸Theragent Inc, Arcadia, CA, ⁹Inotiv, Rockville, MD
Background/Purpose: Current standard of care chronic inflammatory disease therapies are designed to suppress inflammation and are not optimized for inflammation resolution and restoration of tissue…
Abstract Number: 0724 • ACR Convergence 2023
Synovial Macrophage Subsets Defined by ScRNAseq Demonstrate Sexually Dimorphic Gene Expression in RA and a Mouse Inflammatory Arthritis Model
Richard Bell, Ewurama Cann, Chao Yang, Accelerating Medicine Partnership Rheumatoid Arthritis, Amit Lakhanpal, Laura Donlin and Lionel Ivashkiv, Hospital for Special Surgery, New York, NY
Background/Purpose: Macrophages (MФ) play a key pathogenic role in Rheumatoid Arthritis (RA), a disease that exhibits female sex bias. Recent work using scRNAseq has defined…
Abstract Number: 1766 • ACR Convergence 2023
Inflammatory Priming of the Joints via Pre-activation of Macrophages by Anti-MAA Antibodies in Rheumatoid Arthritis
Marcelo Afonso¹, Jitong Sun¹, Koji Sakuraba¹, Anca Catrina¹, Aase Hensvold², Caroline Grönwall¹ and Bence Réthi¹, ¹Karolinska Institutet, Stockholm, Sweden, ²Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institutet. Center for Rheumatology, Academic Specialist Center, Stockholm, Sweden
Background/Purpose: We have previously shown that certain malondialdehyde/acetaldehyde modified protein binding autoantibodies (anti-MAA), obtained from the inflamed joints of rheumatoid arthritis (RA) patients, induced osteoclast…
Abstract Number: 0798 • ACR Convergence 2023
A Novel 3D Model of Rheumatoid Arthritis Synovial Tissue Incorporating Fibroblasts, Endothelial Cells and Macrophages
Eva Philippon¹, Lisanne van Rooijen¹, Jan Piet van Hamburg¹, Fatemeh Khodadust¹, Conny Van der Laken² and Sander Tas³, ¹Amsterdam University Medical Centers, Amsterdam, Netherlands, ²Amsterdam UMC - location VUMC, Amsterdam, Netherlands, ³Amsterdam UMC, locatie AMC, Utrecht, Netherlands
Background/Purpose: Rheumatoid Arthritis (RA) is a progressive and systemic autoimmune disorder associated with chronic and destructive inflammation of the joints. The hallmarks of RA are…
Abstract Number: 1775 • ACR Convergence 2023
The Peptidyl Arginine Deiminase Inhibitor BB-CLA Decreases the Inflammatory and Fibrotic Responses in Macrophages and Rheumatoid Arthritis Synovial Fibroblasts Exposed to Fibrinogen Modified with Malondialdehyde-Acetaldehyde Adduct and Citrulline
Jack Mordeson¹, Nozima Aripova¹, Michael Duryee¹, James O'Dell¹, Bryant England¹, Daniel Anderson¹, Ted R Mikuls² and Geoffrey Thiele¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Peptide citrullination and adduction with malondialdehyde-acetaldehyde adduct (MAA) are post-translational modifications involved in the pathogenesis of rheumatoid arthritis (RA). Anti-cyclic-citrullinated peptide antibodies are >90%…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].